Drug intelligence / Profile preview

nadh

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

NADH (nicotinamide adenine dinucleotide + hydrogen) is a coenzyme that occurs naturally in the body and plays a central role in cellular energy production. It is the reduced form of NAD+ and functions as an electron carrier in redox reactions, donating electrons to various biochemical processes. NADH is involved in the chemical process that generates energy in cells and is essential for metabolic functions.

Brand names: EnBrace HREnadaEnLyte
Other names: Nicotinamide adenine dinucleotide (reduced)DPNHNAD reduced formReduced nicotinamide adenine diphosphateReduced nicotinamide-adenine dinucleotide1,4-dihydronicotinamide adenine dinucleotideB-DPNHBNADHCoenzyme 1Coenzyme1Coenzyme-1

Targets

ND1 (Mitochondrial electron transport chain complex I)

Beyond the preview

Go deeper on nadh.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nadh.

Explore the full profile